Previsioni
| Acquista |
6 |
| Mantieni |
5 |
| Vendi |
2 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Spero Therapeutics receives $105 million from KKR unit, stock falls
Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » Altro su de.investing.com
Spero Therapeutics secures $105 million financing from KKR unit for SP001 development
Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » Altro su de.investing.com
Spero Therapeutics rises 16% after FDA approval for Utebzi
Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » Altro su de.investing.com
Spero Therapeutics: board member Mahadevia resigns, SEC ends investigation
Dr. Ankit Mahadevia has resigned from the board of Spero Therapeutics with immediate effect and has also relinquished his committee and subsidiary mandates; the company cites other professional commitments for the resignation. Spero plans to engage Mahadevia as a consultant to continue supporting management. The U.S. securities regulator SEC said that, based on available information, it currently does not intend to pursue enforcement actions against Spero. In addition, the FDA’s re‑filing of the NDA for the oral carbapenem tebipenem HBr triggers an expected $25 million milestone payment to Spero in Q1 2026, subject to acceptance of the filing. » Altro su de.investing.com
Spero Therapeutics beats Q2 expectations and stock rises
Spero Therapeutics reported Q2 2025 EPS of -$0.03 on revenue of $14.2 million, both well above expectations, and the stock rose double‑digit after the results. The company sharply reduced its net loss, extended its financing runway to 2028, and views Tebipenem HBr—after a successful Phase‑3 study—as on track for possible FDA approval in 2026. Challenges remain in the SPR720 program, and dependence on milestone payments continues to be a risk. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2015, SPERO THERAP.INC. DL-,001 ha già distribuito 0,0534 € di dividendi. L'ultimo pagamento è avvenuto a ottobre 2015.
Dati finanziari
Nell'ultimo trimestre, SPERO THERAP.INC. DL-,001 ha registrato ricavi pari a 0 € e un utile netto di -39,09 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | 100,00% |
| Utile lordo | 0 | 100,00% |
| Utile netto | -39,09 Mln | 521,43% |
| EBITDA | -6,1 Mln | 2,27% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 46,41 Mln € |
Numero di azioni | 58,26 Mln |
Massimo/minimo a 52 settimane | 2,81 € - 0,79 € |
| Dividendi | No |
Beta | 1,56 |
Rapporto P/E | -1,78 |
Rapporto PEG | 0,00 |
Rapporto P/B | 65,16 |
Rapporto P/S | 1,28 |
Profilo aziendale
Spero Therapeutics, Inc., una società biofarmaceutica in fase clinica, si concentra sull'identificazione, sviluppo e commercializzazione di trattamenti per le infezioni batteriche multiresistenti ai farmaci (MDR) e per le malattie rare negli Stati Uniti. I candidati prodotto dell'azienda includono tebipenem pivoxil bromidrato (HBr), un antibiotico orale della classe dei carbapenemi per il trattamento delle infezioni complicate del tratto urinario, inclusa la pielonefrite negli adulti; SPR206, un agente ad azione diretta somministrato per via endovenosa per il trattamento delle infezioni batteriche MDR Gram-negative in ambito ospedaliero; e SPR720, un antibiotico orale per il trattamento della malattia polmonare da micobatteri non tubercolari. L'azienda ha un accordo di licenza con Meiji Seika Pharma Co., Ltd. a supporto dello sviluppo di tebipenem HBr; un accordo di licenza con Everest Medicines per sviluppare, produrre e commercializzare SPR206 in Cina continentale, Hong Kong, Macao, Taiwan, Corea del Sud e paesi del Sud-est asiatico; un accordo di collaborazione con il Bill & Melinda Gates Medical Research Institute per sviluppare SPR720 per il trattamento delle infezioni polmonari causate da Mycobacterium tuberculosis; e un accordo di licenza con Vertex Pharmaceuticals Incorporated relativo a brevetti riguardanti SPR720, nonché SPR719, un metabolita attivo. La società è stata fondata nel 2013 ed ha sede a Cambridge, Massachusetts.
| Nome | SPERO THERAP.INC. DL-,001 |
| CEO | Esther Rajavelu |
| Sede centrale | Cambridge,
ma Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 02/11/2017 |
| Dipendenti | 25 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | SPRO |
Frankfurt | 2HA.F |
Düsseldorf | 2HA.DU |
München | 2HA.MU |